Cellebrite DI (CLBT) – Analysts’ Recent Ratings Changes

Cellebrite DI (NASDAQ: CLBT) has recently received a number of price target changes and ratings updates:

• 8/27/2026 – Cellebrite DI was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 8/14/2026 – Cellebrite DI had its price target lowered by Lake Street Capital from $21.00 to $15.00. They now have a “buy” rating on the stock.
• 8/14/2026 – Cellebrite DI had its price target lowered by JPMorgan Chase & Co. from $20.00 to $16.00. They now have an “overweight” rating on the stock.
• 8/14/2026 – Cellebrite DI had its price target lowered by DA Davidson from $22.00 to $15.00. They now have a “buy” rating on the stock.
• 8/14/2026 – Cellebrite DI had its price target lowered by Needham & Company LLC from $15.00 to $12.50. They now have a “buy” rating on the stock.
• 8/13/2026 – Cellebrite DI was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 8/6/2026 – Cellebrite DI had its price target raised by DA Davidson from $20.00 to $22.00. They now have a “buy” rating on the stock.

Insider Activity at Cellebrite DI

In other Cellebrite DI news, CMO David Gee sold 4,323 shares of Cellebrite DI stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $11.36, for a total value of $49,109.28. Following the transaction, the chief marketing officer owned 135,281 shares in the company, valued at $1,536,792.16. The trade was a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CRO Marcus Jewell sold 12,562 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.24, for a total transaction of $141,196.88. Following the completion of the sale, the executive owned 427,128 shares in the company, valued at $4,800,918.72. This represents a 2.86% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 329,658 shares of company stock worth $4,970,967. 5.70% of the stock is owned by corporate insiders.

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.